Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma ; day:11 ; month:11 ; year:2021
South Asian journal of cancer ; (11.11.2021)
- Contributor
-
Cyriac, Sanju
Toms, Ajith
Thomas, Sunitha
- DOI
-
10.1055/s-0041-1731911
- URN
-
urn:nbn:de:101:1-2022031921303177512584
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cyriac, Sanju
- Toms, Ajith
- Thomas, Sunitha
Other Objects (12)
![The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]](/assets/placeholder/searchResultMediaUnknown.png)
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report